Cantor Fitzgerald

Selected news for Cantor Fitzgerald, representing 1% of data collected since 10/2017. Recent stories appear in dispatchtribunal.com. This capital firm shares healthcare news with Vocera, Tabula Rasa HealthCare, Teladoc, Benefitfocus, Pfizer and over a hundred others.

Please provide a valid email address.

Selected Headines

Date Headline (link) Source Relevant Snippet
1/3/2021 Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Lowered by BidaskClub Daily Political ... Therapeutics in a research report on Tuesday, September 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of Bicycle Therapeutics in a report on Thursday, December 3rd. Cantor Fitzgerald initiated coverage on shares of Bicycle Therapeutics in a report on Monday, October 12th. They issued an “overweight” rating and a $30.00 target price on the stock. Zacks Investment Research raised shares of ...
1/3/2021 DURECT (NASDAQ:DRRX) Stock Rating Upgraded by Zacks Investment Research Daily Political ... drug formulations. “Several other analysts have also weighed in on DRRX. TheStreet lowered shares of DURECT from a “c-” rating to a “d” rating in a research report on Tuesday, November 3rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of DURECT in a research note on Friday, October 9th. Roth Capital began coverage on DURECT in a report on Monday, October 12th. They issued a “buy ...
1/1/2021 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Post FY2021 Earnings of ($1.24) Per Share, Cantor Fitzgerald Forecasts zolmax.com ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Post FY2021 Earnings of ($1.24) Per Share, Cantor Fitzgerald Forecasts Posted by Bonnie Powley on Jan 1st, 2021 TweetACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Cantor Fitzgerald lowered their FY2021 earnings estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Tuesday, December 29th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will post ...
1/1/2021 Cantor Fitzgerald Comments on GW Pharmaceuticals plc's FY2020 Earnings (NASDAQ:GWPH) Daily Political GW Pharmaceuticals plc (NASDAQ:GWPH) – Equities researchers at Cantor Fitzgerald boosted their FY2020 earnings per share (EPS) estimates for GW Pharmaceuticals in a research note issued on Tuesday, December 29th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will post earnings of ($1.80) per share for the year, up from their prior estimate of ($2.16). Cantor Fitzgerald has a “Overweight” rating and a $147.00 price ...
1/1/2021 Change Healthcare (NASDAQ:CHNG) Lowered to “Buy” at BidaskClub Daily Political ... on Monday, September 14th. CSFB increased their price target on shares of Change Healthcare from $16.00 to $19.00 and gave the company an outperform rating in a research note on Monday, September 28th. Finally, Cantor Fitzgerald increased their price target on shares of Change Healthcare from $17.00 to $18.00 and gave the company an overweight rating in a research note on Thursday, November 5th. One equities research analyst has rated ...
1/1/2021 Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded to Sell at BidaskClub dispatchtribunal.com ... price for the company in a research report on Tuesday, November 10th. BMO Capital Markets cut their target price on Agios Pharmaceuticals from $57.00 to $50.00 in a report on Wednesday, December 9th. Finally, Cantor Fitzgerald raised their price objective on Agios Pharmaceuticals from $68.00 to $79.00 and gave the stock an overweight rating in a research report on Thursday, November 19th. One research analyst has rated the stock with ...
1/1/2021 Tivity Health (NASDAQ:TVTY) Upgraded by BidaskClub to Strong-Buy dispatchtribunal.com ... Health (NASDAQ:TVTY) from a buy rating to a strong-buy rating in a research note released on Monday morning, BidAskClub reports.Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald raised Tivity Health from a neutral rating to an overweight rating and set a $25.00 price target for the company in a research report on Tuesday, November 17th. Piper Sandler boosted their price target ...
1/1/2021 Aphria (NYSE:APHA) Cut to “Sell” at Zacks Investment Research rivertonroll.com ... a report on Thursday, December 17th. Alliance Global Partners boosted their target price on Aphria from $9.00 to $12.00 and gave the company a buy rating in a research note on Wednesday, December 16th. Cantor Fitzgerald dropped their price target on Aphria from $15.50 to $11.75 and set an overweight rating for the company in a research note on Friday, October 16th. Finally, Canaccord Genuity cut shares of Aphria from ...
1/1/2021 Aphria (NYSE:APHA) Downgraded by Zacks Investment Research thelincolnianonline.com ... Get Aphria alerts:A number of other brokerages have also recently commented on APHA. Stifel Nicolaus cut Aphria from a buy rating to a hold rating in a research note on Thursday, December 17th. Cantor Fitzgerald decreased their price target on shares of Aphria from $15.50 to $11.75 and set an overweight rating for the company in a research note on Friday, October 16th. CIBC raised their price objective on ...
1/1/2021 UnitedHealth Group (NYSE:UNH) Upgraded to Sell at BidaskClub thelincolnianonline.com ... rating in a report on Monday, October 19th. Barclays boosted their price objective on UnitedHealth Group from $322.00 to $365.00 and gave the company an overweight rating in a report on Tuesday, October 13th. Cantor Fitzgerald upped their target price on UnitedHealth Group from $360.00 to $375.00 and gave the company an overweight rating in a report on Wednesday, December 2nd. Morgan Stanley upped their target price on UnitedHealth Group ...
1/1/2021 Amgen Inc. to Post FY2023 Earnings of $18.52 Per Share, Oppenheimer Forecasts (NASDAQ:AMGN) Ticker Report ... Get Amgen alerts: AMGN has been the subject of several other research reports. ValuEngine downgraded Amgen from a “hold” rating to a “sell” rating in a research note on Thursday, October 8th. Cantor Fitzgerald cut their target price on Amgen from $279.00 to $278.00 and set an “overweight” rating for the company in a research note on Thursday, October 29th. JPMorgan Chase & Co. restated a “hold” ...
1/1/2021 Aptose Biosciences (NASDAQ:APTO) Upgraded at Zacks Investment Research slatersentinel.com ... with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “ Get Aptose Biosciences alerts:A number of other research firms have also recently commented on APTO. Cantor Fitzgerald assumed coverage on Aptose Biosciences in a research note on Monday, October 19th. They set an overweight rating and a $10.00 target price on the stock. Alliance Global Partners began coverage on shares of ...
1/1/2021 Cantor Fitzgerald Reaffirms Overweight Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) slatersentinel.com ... Pharmaceuticals (NASDAQ:ACAD) Posted by Carol Hyndes on Jan 1st, 2021Cantor Fitzgerald reissued their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research note published on Tuesday, The Fly reports. Cantor Fitzgerald currently has a $70.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $61.00. Cantor Fitzgerald also issued estimates for ACADIA Pharmaceuticals’ FY2021 earnings at ($1.24) EPS ...
1/1/2021 Aptose Biosciences (NASDAQ:APTO) Raised to “Buy” at Zacks Investment Research zolmax.com ... with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “ Get Aptose Biosciences alerts:Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald initiated coverage on Aptose Biosciences in a research note on Monday, October 19th. They issued an overweight rating and a $10.00 target price on the stock. BidaskClub lowered shares of Aptose Biosciences from a ...
1/1/2021 Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Receives Average Recommendation of “Buy” from Analysts dispatchtribunal.com ... have commented on CURLF shares. Needham & Company LLC increased their price target on Curaleaf from $13.50 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, November 18th. Cantor Fitzgerald increased their price target on Curaleaf from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, November 18th. Canaccord Genuity raised their price objective on Curaleaf ...